We describe a sol-gel synthetic method for the production of praseodymium-doped yttrium aluminum garnet (YAG) nanoparticles suitable for X-ray inducible photodynamic therapy (X-PDT). Our sol-gel based approach was optimized by varying temperature and time of calcination, resulting in nanoparticles that were smooth, spherical, and 50-200 nm in crystallite size. The powders were uniformly coated with a thin (10 nm) layer of silica to facilitate surface conjugation with functional moieties. Measurements of photon flux revealed that coated and uncoated powders emitted a similar photon emission spectrum in response to 50 keVp X-rays. We also determined that the presence of silica did not significantly reduce flux and the emission peak had a maximum at approximately 320 nm. Thus, these YAG:Pr powders are suitable candidates for future in vivo X-PDT studies.
Introduction
Cancer is a leading cause of death and virtually all front-line chemotherapy drugs and radiation therapies are nonspecific, leading to systemic toxicity and acquired resistance. Hence, radiation oncologists have long proposed the concept of a prodrug that is activated by radiation only at a tumor site. Such a prodrug, administered in a nontoxic form, would circulate through the blood and be taken up by the tumor, where it would be activated with a radiation beam aimed only at the tumor [1] . This strategy allows for delivery of high doses of prodrug that is activated only at the site of interest, thereby reducing off target side effects. The development of radiation prodrugs has been stymied because dissolved oxygen, which is ubiquitous in mammalian tissues, quenches chemical species needed to trigger prodrug activation [2] [3] [4] [5] . A recent approach, X-ray inducible photodynamic therapy (X-PDT) [6] , offers a potential solution based on radiation scintillator materials that emit light in response to ionizing radiation such as X-rays [7] . The X-PDT concept makes use of an inactive light sensitive prodrug or a photosensitizer, which produces singlet oxygen upon exposure to emitted light, coupled to a scintillator nanoparticle [8] . The nanoparticles, when injected into the blood, are expected to mainly distribute to tumor tissue, as well as the liver and spleen from which they will eventually clear [9] . After distribution, ionizing radiation directed only at the tumor triggers scintillator light emission to locally induce prodrug conversion or photosensitizer activation and, in fact, X-PDT has elicited tumor shrinkage in animal tumor models [10] .
A variety of scintillator materials have been proposed for X-PDT, including and be able to effectively accumulate in tumor tissue. These include proper crystallite size of the powders, to take advantage of tumor accumulation via the enhanced permeability and retention (EPR) effect, and smooth spherical particles to minimize blood vessel wall damage and to allow uniform loading of the desired payload [17, 18] . For passive targeting via EPR, optimal crystallite size is generally agreed to be between 10 and 200 nm [19] . Crystallite sizes that are too large will be rapidly removed by the reticuloendothelial and hepatic systems, while crystals smaller than 5 nm will be quickly cleared by the kidneys [20] . Thus, the preparation of spherical, smooth, and appropriately sized scintillator powders is critical for their use in X-PDT. However, the majority of reported YAG powders, have not been prepared for biological applications and are not appropriately configured for in vivo use.
Moszynski et al. [21] was among the first to synthesize rare earth doped YAG powders, but did not characterize their size and shape. Zhou et al. [12] produced yttrium-based particles, which were too small for most biomedical applications involving intravenous administration. Additionally, their TEM images appeared to show irregularly-shaped particles. Other compositions have also possessed disqualifying properties. For example, Chen et al. [6] developed SrAl 2 O 4 :Eu 2+ loaded with a photosensitizer, namely merocyanine 540 (MC540) that yielded cytotoxic oxygen species when exposed to light. These irregularly-shaped particles were smoothed with a comparatively thick silica coating, but were unstable and ultimately too large (mean diameter = 407.4 ± 152. 5 nm) for relevant preclinical development in animal models and especially for clinical use in patients. In this context, and given the compelling attributes of YAG:Pr scintillator materials, we were motivated to develop a sol-gel synthetic methodology for the preparation of YAG nanocrystals that could be evenly and thinly coated. Sol-gel powder fabrication techniques have been reported to offer superior shape and size control for the preparation of YAG [22] [23] [24] [25] [26] [27] . The process can be effective with appropriate selection of precursors and calcination temperature and time.
In this report, we present an optimized sol-gel based scheme for the production of silica-coated YAG:Pr scintillator nanoparticles displaying the desired physical shape and size characteristics for X-PDT applications. The specific criteria used to assess the YAG: Pr scintillator included an emitted light wavelength between 300 and 400 nm, spherical or near-spherical crystal shape, a uniform and smooth surface, and crystallite diameters between 50 and 200 nm. 3 were dissolved in 75 mL of methanol. The solution was stirred at 400 rpm for approximately 48 h (until the entire liquid methanol had evaporated). The mostly dry, whitish-yellow product was then removed from the beaker and crushed with a mortar and pestle in preparation for pre-calcination. The crushed powders were heated in a box furnace (SenroTech) for 1 h at 500°C (precalcination step) to remove carbon impurities. Powders were calcined at different temperatures for varying times: 2 h at 1000°C, 2 h at 1100°C, 2 h at 1200°C, 1 h at 1350°C, and 1 h at 1400°C. The calcination time was chosen to be 1-2 h to prevent undesired nanoparticle growth. Additionally, the calcination procedure for the samples calcined at 1000°C, 1100°C, and 1200°C consisted of 3 h ramp up and 3 h ramp down stages of the heating and cooling processes. The samples calcined at 1350°C and 1400°C were placed in the furnace preheated to the maximum calcination temperature, that is, there was no ramp up and ramp down stages. For application of the silica coating, the YAG:Pr powders were diluted in ethanol at 0.1 mg/mL. Tetramethyl orthosilicate (TMOS) [MW = 152.22, purity = 98%, vapor density = 5.25 (vs air), Sigma-Aldrich] was hydrolyzed in 1 mM HCl at 14% by volume to form silicic acid. Typically, 3.75 mL TMOS and 25 mL 1 mM HCl for 1 min was used. To coat the powders, a mixture of 0.05% (v/v) silicic acid was prepared with the solution containing 0.01 mg/mL of particles and vortexed overnight at room temperature. The unreacted silicic acid was removed by centrifuging the coated particles and washing with ethanol three times. To reduce aggregation, samples were probe sonicated using a QSonica Q125 (QSonica, Newton, CT) at 30% amplitude for 2 min.
Experimental procedures
Phases of the powders were characterized by X-ray diffraction (XRD) on a D2 Phaser (Bruker AXS, Madison, WI) using a step size of 0.02°2h and a count time of 1 s by scanning from 15 to 85°2h. Particle morphology of uncoated and coated powders were observed using a G2 Sphera (FEI Company, Hillsboro, OR) transmission electron microscope (TEM) using a 200 keV accelerating voltage. For TEM sample preparation, powders were dissolved in acetone (1 mg/mL), ultrasonicated for 15 min, and stirred for 15 min. Subsequently, the solution containing dispersed powder was dropped onto a thin carbon-coated copper TEM grid. The luminescence of the samples was measured by placing 265 mg of YAG:Pr powder in glass cuvettes of approximately 500 lL volume. The samples were excited by a continuous unfiltered X-ray beam from a Nonius FR591 water-cooled rotating copper-anode X-ray generator (Bruker AXS Inc., Madison, WI) set at 50 kV and 60 mA. The emission spectra were measured with a SpectraPro-2150i spectrometer (Acton Research Corp., Acton, MA) coupled to a PIX-IS:100B charge-coupled detector (CCD) (Princeton Instruments, Inc., Trenton, NJ). The spectrometer has a motorized ordersorting filter wheel, a motorized slit, and two diffraction gratings (blazed for 300 and 500 nm) mounted on a turret. The ordersorting filters eliminated all second or higher order peaks. Three exposures were used to cover the 200-1000 nm range.
Results and discussion
The X-ray diffraction patterns for the powders at different temperatures and times of calcination are illustrated in Fig. 1 Fig. 1(a) and (b) ), while it became significantly smaller at 1200°C (Fig. 1(c) ), a qualitative assessment based on the height of the peaks. This phase is almost completely eliminated at the higher temperatures of 1350°C and 1400°C ( Fig. 1(d) and (e) ). There were no YAG peaks at temperatures less than 1100°C and, instead, prominent YAM and YAP peaks were observable ( Fig. 1(a) and  (b) ). This is in contrast to other sol-gel based studies, which report the presence of YAG at 800°C [22] , 900°C [23] , 950°C [24] , and 1000°C [25] . These differences can be attributed to relatively minor variations in preparative methods and/or differences in precursors. For example, Zhou et al. [22] , prepared YAG powders through a polymer-assisted sol-gel method with citric acid, acrylamide (AAM), and N,N 0 -methylenebisacrylamide (MBAAm) introduced into the solution before it was dried into a powder. Marin et al. [25] made use of heating to 100°C with stirring, whereas Li et al. [23] and Ruan et al. [24] used stabilizing acids with heated stirring. Our study did not incorporate acid-based stabilization and heat was not applied during the stirring step of the synthesis process.
As calcination temperature increased from 1100°C to 1200°C, the powder diffraction pattern began to match that of the YAG phase (compare Fig. 1(b) and Fig. 1(c) ). Furthermore, the YAM phase disappeared at 1100°C, and the YAP phase became less evident between 1000°C and 1100°C; both of these phases almost completely vanished by 1200°C (Fig. 1(c) ). These results agree with Ogi et al. [26, 27] who reported the preparation of YAG:Ce by sol-gel synthesis and calcination at 1400°C, but did not comment on the status of YAM or YAP phases at lower calcination temperatures. Our results also corroborate with those of Li et al. [23] and Ruan et al. [24] who reported the sol-gel synthesis of YAG powders using co-precipitated precursors different from ours. In addition, a study by Simoneko et al. [28] showed YAG and YAP phases in a powder prepared by heating a xerogel in air flow at a temperature of 990°C, while only YAG was present in powder calcined at 1200°C.
Empirically, the 1400°C calcination treatment results in optimum powders because of a balance between the formation of the desired YAG phase, the shortened calcination time (1 h vs. 2 h) that minimizes agglomeration, and diffusion processes during nanoparticle growth that may help in eliminating jagged edges. Thus, the powders calcined at 1400°C were used for subsequent coating with silica to provide a means of conjugating functional molecules, such as targeting ligands to the particle surfaces. Fig. 2(a) and (b) illustrates the YAG:Pr powders coated with silica, which formed a uniform and thin (10 nm) layer. Silica was chosen as it is non-toxic, FDA approved, and amenable to a variety of surface chemistries through silanol groups [29] .
The particle photon emission spectra for the uncoated and silica coated YAG:Pr particles, in response to 50 keVp X-rays, is provided in Fig. 3 . The silica coating reduced the measured peak photon flux by about 25%, as it served as a barrier to light transmission. Nonetheless, as shown by Fig. 3 , the absolute photon flux was still robust and the peak wavelength was unaffected, remaining at 320 nm. Hence, we conclude that the silica coated particles exhibit an emission spectrum that is operationally similar compared to the uncoated particles. This suggests that coating YAG:Pr particles with silica may be a feasible approach for introducing functional groups to the particle surfaces and will not adversely compromise nanoscintillator photon emission.
In summary, the regular surface of the YAG:Pr nanoparticles allowed the efficient and complete coating with a 10 nm layer of silica for further surface functionalization. Some of the agglomeration was resolvable by mild ultrasonication and the coated particles exhibited a minimal reduction in photon flux during radiation exposure due to the coating. Given these attributes, we believe that our YAG:Pr powders are well-suited for further development in an X-PDT treatment system.
Conclusions
We describe the preparation of smooth, spherical scintillator nanoparticles of (Y 1Àx Pr x ) 3 Al 5 O 12 (YAG:Pr) with x = 0.01. The optimized sol-gel process was straightforward and included the key step of calcination at 1400°C for 1 h. Corresponding phases and crystallite sizes of the powders were characterized by X-ray diffraction, together with transmission electron microscopy (TEM), while particle sizes and morphologies were evaluated by TEM. The overall diameter of the nanocrystals was found to be less than 200 nm. Moreover, a uniform coating of the crystals with a thin, functionalizing silica layer proved to be feasible. Coated and uncoated powders exhibited a similar photon emission profile, and photon flux with coated particles remained robust. Collectively, these observations suggest that sol-gel prepared YAG:Pr nanoparticles may be suitable for in vivo preclinical and clinical X-PDT studies.
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